Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib

Neda Stjepanovic, Jaume CapdevilaDepartment of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, SpainAbstract: Thyroid cancers are the most frequent neoplasms of the endocrine system and in the initial stages their prognosis is excellent. However, few therapeutic options are...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stjepanovic N, Capdevila J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/f48bfc139a3143eab3a20b5125564756
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f48bfc139a3143eab3a20b5125564756
record_format	dspace
spelling	oai:doaj.org-article:f48bfc139a3143eab3a20b51255647562021-12-02T11:17:52ZMultikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib1177-5475https://doaj.org/article/f48bfc139a3143eab3a20b51255647562014-04-01T00:00:00Zhttp://www.dovepress.com/multikinase-inhibitors-in-the-treatment-of-thyroid-cancer-specific-rol-a16433https://doaj.org/toc/1177-5475 Neda Stjepanovic, Jaume CapdevilaDepartment of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, SpainAbstract: Thyroid cancers are the most frequent neoplasms of the endocrine system and in the initial stages their prognosis is excellent. However, few therapeutic options are available for advanced or metastatic disease. In the last decade, a better understanding of the molecular events involved in the tumorigenesis of thyroid cancers has led to development of new targeted agents for the management of advanced and refractory disease. Multikinase inhibitors that are able to block pathways involved in the proliferation, invasion, and neoangiogenesis of thyroid cancer have been the most widely studied. After an international effort to identify and recruit sufficient patients, four placebo-controlled studies of multikinase inhibitors have been completed. These trials have led to the approval of the first agents with activity in advanced medullary thyroid cancers, which will probably change the landscape of treatment for iodine-refractory differentiated thyroid cancer in the near future. The purpose of this paper is to review the development of targeted agents for thyroid malignancy, with a special focus on lenvatinib, a multikinase inhibitor.Keywords: thyroid cancer, lenvatinib, tyrosine kinase inhibitors, multikinase inhibitors, targeted therapiesStjepanovic NCapdevila JDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2014, Iss default, Pp 129-139 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Stjepanovic N Capdevila J Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
description	Neda Stjepanovic, Jaume CapdevilaDepartment of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, SpainAbstract: Thyroid cancers are the most frequent neoplasms of the endocrine system and in the initial stages their prognosis is excellent. However, few therapeutic options are available for advanced or metastatic disease. In the last decade, a better understanding of the molecular events involved in the tumorigenesis of thyroid cancers has led to development of new targeted agents for the management of advanced and refractory disease. Multikinase inhibitors that are able to block pathways involved in the proliferation, invasion, and neoangiogenesis of thyroid cancer have been the most widely studied. After an international effort to identify and recruit sufficient patients, four placebo-controlled studies of multikinase inhibitors have been completed. These trials have led to the approval of the first agents with activity in advanced medullary thyroid cancers, which will probably change the landscape of treatment for iodine-refractory differentiated thyroid cancer in the near future. The purpose of this paper is to review the development of targeted agents for thyroid malignancy, with a special focus on lenvatinib, a multikinase inhibitor.Keywords: thyroid cancer, lenvatinib, tyrosine kinase inhibitors, multikinase inhibitors, targeted therapies
format	article
author	Stjepanovic N Capdevila J
author_facet	Stjepanovic N Capdevila J
author_sort	Stjepanovic N
title	Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
title_short	Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
title_full	Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
title_fullStr	Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
title_full_unstemmed	Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
title_sort	multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/f48bfc139a3143eab3a20b5125564756
work_keys_str_mv	AT stjepanovicn multikinaseinhibitorsinthetreatmentofthyroidcancerspecificroleoflenvatinib AT capdevilaj multikinaseinhibitorsinthetreatmentofthyroidcancerspecificroleoflenvatinib
_version_	1718396092074164224

Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib

Ejemplares similares